Kelly Lawrence W & Associates’s Allergan plc AGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-10,873
Closed -$1.59M 135
2019
Q1
$1.59M Sell
10,873
-400
-4% -$58K 0.29% 41
2018
Q4
$1.51M Sell
11,273
-44,536
-80% -$7.3M 0.33% 40
2018
Q3
$10.6M Buy
55,809
+385
+0.7% +$70.7K 1.75% 26
2018
Q2
$9.24M Sell
55,424
-370
-0.7% -$59.4K 1.7% 25
2018
Q1
$9.39M Buy
55,794
+3,670
+7% +$616K 1.78% 24
2017
Q4
$8.53M Buy
52,124
+13,425
+35% +$2.41M 1.57% 26
2017
Q3
$7.93M Buy
38,699
+1,608
+4% +$374K 1.51% 27
2017
Q2
$9.02M Buy
37,091
+26,370
+246% +$6.2M 1.78% 24
2017
Q1
$2.56M Buy
10,721
+1,747
+19% +$407K 0.53% 41
2016
Q4
$1.88M Sell
8,974
-36,925
-80% -$7.65M 0.42% 42
2016
Q3
$10.6M Buy
45,899
+668
+1% +$163K 2.26% 22
2016
Q2
$10.5M Buy
45,231
+44,708
+8,548% +$10.3M 2.42% 18
2016
Q1
$140K Hold
523
0.04% 97
2015
Q4
$163K Hold
523
0.04% 94
2015
Q3
$142K Sell
523
-1,651
-76% -$507K 0.03% 99
2015
Q2
$660K Sell
2,174
-846
-28% -$252K 0.13% 56
2015
Q1
$899K Buy
+3,020
New +$861K 0.19% 44

Other funds holding AGN

Kelly Lawrence W & Associates's AGN Position: Q2 2019 in Review

Kelly Lawrence W & Associates sold out of Allergan plc (AGN) in Q2 2019, closing a stake of 10,873 shares — an estimated $1.59M sold.

Kelly Lawrence W & Associates first reported a position in AGN in Q1 2015 and held it in 17 quarters. The position peaked at $10.6M in Q3 2018. 971 funds tracked by Wall St. Rank hold AGN as of Q2 2019.

  • Kelly Lawrence W & Associates reported no remaining Allergan plc position as of Q2 2019 after selling out during the quarter.
  • Kelly Lawrence W & Associates sold 10,873 Allergan plc shares in Q2 2019, an estimated $1.59M.
  • Kelly Lawrence W & Associates first reported a position in Allergan plc in Q1 2015 and held it in 17 quarters.
  • Kelly Lawrence W & Associates's Allergan plc position peaked at $10.6M in Q3 2018.
  • 971 funds tracked by Wall St. Rank held Allergan plc as of Q2 2019.

Based on Kelly Lawrence W & Associates's 13F filing for Q2 2019, filed 14 Aug 2019.